Fycompa tablets 4 mg for epilepsy

General information on Japanese Fycompa tablets 4 mg for epilepsy    

Package details: 56 tablets

Manufacturer: Eisai Co. Ltd., Japan

Active ingredient: perampanel hydrate (chemical formula C92H66N12O7)

Medical effect: Fycompa tablets are effective for the following purposes:

• calming excessively excited nerves in the brain,
• treating partial seizures (including secondary generalized seizures) in epileptic patients,
• treating tonic-clonic attacks in patients with epilepsy,
• suppressing epileptic attacks in epileptic patients with inadequate response to other antiepileptic agents.

Contraindications and precautions: do not use in patients with liver dysfunction. Do not use in pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Avoid drinking alcohol while taking this medication. As the medicine may cause drowsiness, avoid driving a car or operating dangerous machinery while taking this medication. Avoid taking any food containing St. John's wort while taking this medication.

Dosage and administration of Japanese Fycompa tablets 4 mg for epilepsy 

For adults and children 12 years old or more, start with 2 mg of active ingredient at a time, once a day, before bedtime. Please note that this medicine contains 4 mg of perampanel in a tablet. Gradually increase the dosage by 2 mg at an interval of 1 week or longer.

If this medicine is taken concomitantly with other antiepileptic agents that promote the metabolism of this medicine, the maintenance dose is 8-12 mg of perampanel once a day. If Fycompa tablets are taken as an only medicine, the maintenance dose is 8 mg once a day. The maximum daily dose of 12 mg should not be exceeded.

The dosage may be adjusted by the consulting doctor due to age and symptoms.

How effective are Fycompa tablets 4 mg from Japan for epilepsy?

Fycompa tablets contain 4 mg of perampanel hydrate, a noncompetitive AMPA glutamate receptor antagonist. This substance was developed by Japanese pharmaceutical company Eisai Co. Ltd. and approved in 2012. It is designed for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy. Studies showed that 30.9% of patients treated with Fycompa were free of PGTC seizures during the 13 week maintenance period (F. Besag, Ph. Patsalos. Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures // Neuropsychiatric Disease and Treatment. 2016, 12: 1215–20).

Who should use Fycompa tablets 4 mg from Japan?

Fycompa tablets can be used together with enzyme-inducing antiepileptic drugs or without those. Also, this medicine is suitable for the patients with inadequate response to other antiepileptic agents.